Summary
Amgen Inc. (AMGN) filed an 8-K report on May 24, 2012, announcing significant leadership changes and the outcomes of its 2012 Annual Stockholders' Meeting. The most impactful event is the official transition of CEO duties from Kevin W. Sharer to Robert A. Bradway, effective May 23, 2012. Mr. Sharer will remain as Chairman until his retirement at the end of 2012, providing a transition period. The report also details the election of all 14 director nominees, the ratification of Ernst & Young LLP as independent auditors, and the approval of executive compensation on an advisory basis. Additionally, stockholders approved an amendment to the Restated Certificate of Incorporation to permit stockholder action by written consent, a move that enhances shareholder engagement flexibility. Several stockholder proposals concerning corporate governance, including an independent Chairman and limitations on CEO board service, were put forth but did not receive majority approval. Investors should monitor the integration of Mr. Bradway into the CEO role and the company's continued strategic direction under his leadership.
Key Highlights
- 1Robert A. Bradway has officially been appointed President and Chief Executive Officer (CEO), succeeding Kevin W. Sharer, effective May 23, 2012.
- 2Kevin W. Sharer resigned as CEO but will continue as Chairman of the Board and an employee until his retirement at the end of 2012.
- 3All 14 nominated directors were elected to serve one-year terms.
- 4Ernst & Young LLP was ratified as Amgen's independent registered public accountants for the fiscal year ending December 31, 2012.
- 5Stockholders approved an amendment to the Restated Certificate of Incorporation to authorize stockholder action by written consent.
- 6The advisory vote to approve executive compensation received majority support from stockholders.
- 7Several stockholder proposals, including those for an independent Chairman and limiting CEO board memberships, were not approved by a majority of votes.